Cargando…

Autophagy in BRAF-mutant cutaneous melanoma: recent advances and therapeutic perspective

Macroautophagy, hereafter referred to as autophagy, represents a highly conserved catabolic process that maintains cellular homeostasis. At present, the role of autophagy in cutaneous melanoma (CM) is still controversial, since it appears to be tumor-suppressive at early stages of malignant transfor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fratta, Elisabetta, Giurato, Giorgio, Guerrieri, Roberto, Colizzi, Francesca, Dal Col, Jessica, Weisz, Alessandro, Steffan, Agostino, Montico, Barbara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10310793/ https://www.ncbi.nlm.nih.gov/pubmed/37386023 http://dx.doi.org/10.1038/s41420-023-01496-w

Ejemplares similares

Loss of Spry1 reduces growth of BRAF(V600)-mutant cutaneous melanoma and improves response to targeted therapy
por: Montico, Barbara, et al.
Publicado: (2020)

The pleiotropic roles of circular and long noncoding RNAs in cutaneous melanoma
por: Montico, Barbara, et al.
Publicado: (2021)

Phospholipid scramblase 1: a protein with multiple functions via multiple molecular interactors
por: Dal Col, Jessica, et al.
Publicado: (2022)

Integration of miRNA:mRNA Co-Expression Revealed Crucial Mechanisms Modulated in Immunogenic Cancer Cell Death
por: Lamberti, María Julia, et al.
Publicado: (2022)

Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma
por: Nepote, Alessandro, et al.
Publicado: (2022)

Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies
por: Fratta, Elisabetta, et al.
Publicado: (2016)

Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies
por: Sigalotti, Luca, et al.
Publicado: (2010)

Optimizing the treatment of BRAF mutant melanoma
por: Settleman, Jeff
Publicado: (2014)

Dabrafenib for treatment of BRAF-mutant melanoma
por: Kainthla, Radhika, et al.
Publicado: (2013)

LINE-1 hypomethylation is associated with poor outcomes in locoregionally advanced oropharyngeal cancer
por: Casarotto, Mariateresa, et al.
Publicado: (2022)

BET and BRAF inhibitors act synergistically against BRAF‐mutant melanoma
por: Paoluzzi, Luca, et al.
Publicado: (2016)

Phospholipid scramblase 1 as a critical node at the crossroad between autophagy and apoptosis in mantle cell lymphoma
por: Mastorci, Katy, et al.
Publicado: (2016)

Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges
por: Rizzo, Alessandro, et al.
Publicado: (2020)

Variations of BRAF mutant allele percentage in melanomas
por: Hélias-Rodzewicz, Zofia, et al.
Publicado: (2015)

Novel combination therapies for BRAF-mutant melanoma
por: McArthur, Grant A
Publicado: (2015)

Current Advances in the Treatment of BRAF-Mutant Melanoma
por: Patel, Hima, et al.
Publicado: (2020)

BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells
por: Goulielmaki, Maria, et al.
Publicado: (2016)

Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive BRAF Mutant Advanced Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2023)

Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas
por: Edmunds, S C, et al.
Publicado: (2003)

Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma
por: Doma, V., et al.
Publicado: (2019)

Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2019)

Intermittent BRAF Inhibition Can Achieve Prolonged Disease Control in BRAF Mutant Melanoma
por: Jain, Tania, et al.
Publicado: (2015)

HSPB8 counteracts tumor activity of BRAF- and NRAS-mutant melanoma cells by modulation of RAS-prenylation and autophagy
por: Cristofani, Riccardo, et al.
Publicado: (2022)

Correction to: Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma
por: Doma, V., et al.
Publicado: (2019)

Resistance surveillance in a BRAF mutant melanoma patient on long-term BRAF-inhibitor treatment
por: Mak, Gabriel, et al.
Publicado: (2014)

Upregulation of MicroRNA-1246 Is Associated with BRAF Inhibitor Resistance in Melanoma Cells with Mutant BRAF
por: Kim, Jae-Hyeon, et al.
Publicado: (2017)

Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma
por: Hamid, Omid, et al.
Publicado: (2019)

IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma
por: Patel, Hima, et al.
Publicado: (2021)

Beyond MicroRNAs: Emerging Role of Other Non-Coding RNAs in HPV-Driven Cancers
por: Casarotto, Mariateresa, et al.
Publicado: (2020)

Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications
por: Vanni, Irene, et al.
Publicado: (2020)

Seriniquinones as Therapeutic Leads for Treatment of BRAF and NRAS Mutant Melanomas
por: Hirata, Amanda S., et al.
Publicado: (2021)

AKT2 Loss Impairs BRAF-Mutant Melanoma Metastasis
por: McRee, Siobhan K., et al.
Publicado: (2023)

Development of potent autophagy inhibitors that sensitize oncogenic BRAF V600E mutant melanoma tumor cells to vemurafenib
por: Goodall, Megan L, et al.
Publicado: (2014)

mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition
por: Xue, Gongda, et al.
Publicado: (2017)

Case Report: Dynamic overlap of melanoma, sarcoidosis, and targeted therapy for BRAF-mutant melanoma
por: Dar, Nakul, et al.
Publicado: (2023)

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy
por: Gouda, M.A., et al.
Publicado: (2023)

Immunogenic Apoptosis as a Novel Tool for Anticancer Vaccine Development
por: Montico, Barbara, et al.
Publicado: (2018)

Stability of BRAF V600E mutation in metastatic melanoma: new insights for therapeutic success?
por: Sigalotti, L, et al.
Publicado: (2011)

Cutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of the Literature
por: Gençler, Bilgen, et al.
Publicado: (2016)

Defining the Criteria for Reflex Testing for BRAF Mutations in Cutaneous Melanoma Patients
por: Zhou, Sarah, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_drphj9j1gjjl4g4vpp6eiksa7b